Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020322 | 1.00 | ADORA1 (0.44) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12020312 | 1.00 | ADORA1 (0.44) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12020288 | 0.95 | ADORA1 (0.42) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12535013 | 0.94 | ADORA1 (0.43) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12534879 | 0.94 | ADORA1 (0.45) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12534926 | 0.93 | ADORA1 (0.39) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12534939 | 0.93 | ADORA1 (0.40) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12535009 | 0.93 | ADORA1 (0.40) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL381793 | 0.92 | ADORA1 (0.51) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL1932799 | 0.92 | ADORA1 (0.51) | ADORA1SLC6A3ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | ADORA1 1562/4885SLC6A3 671/4885ADORA2B 1900/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | ADORA1 741/4885SLC6A3 476/4885ADORA2B 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.